Table 5.
FA and MD values [Mean (SD)] in controls; Patients pre-, post- [responders (n = 8), and non-responders (n = 4)] 6 months bumetanide administration.
| Control | Patients | ||||||
|---|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | ||||||
| Location | Side | P-value | Responders | Non-responders | |||
| Forceps major | FA MD e−3 |
0.58 (0.03) 0.79 (0.02) |
0.59 (0.006) 0.8 (0.06) |
0.2 0.22 |
0.56 (0.007) 0.8 (0.06) |
0.56 (0.005) 0.8 (0.01) |
|
| Forceps minor | FA MD e−3 |
0.50 (0.03) 0.8 (0.04) |
0.51 (0.003) 0.8 (0.03) |
0.34 0.91 |
0.50 (0.04) 0.8 (0.04) |
0.51 (0.003) 0.7 (0.02) |
|
| SLFt | FA MD e−3 |
L R L R |
0.48 (0.03) 0.47 (0.03) 75 (0.04) 0.76 (0.03) |
0.48 (0.02) 0.47 (0.05) 82 (0.03) 0.80 (0.03) |
0.0027*
0.47 0.001* 0.42 |
0.48 (0.03) 0.48 (0.03) 0.8 (0.06) 0.8 (0.03) |
0.45 (0.08) 0.47 (0.02) 0.8 (0.01) 0.7 (0.03) |
| SLFp | FA MD e−3 |
L R L R |
0.47 (0.03) 0.45 (0.03) 0.75 (0.03) 0.75 (0.03) |
0.48 (0.04) 0.44 (0.03) 0.79 (0.03) 0.79 (0.04) |
0.54 0.04* 0.15 0.94 |
0.48 (0.06) 0.46 (0.03) 0.8 (0.05) 0. 8 (0.08) |
0.46 (0.02) 0.46 (0.02) 0.8 (0.04) 0. 7 (0.03) |
| ILF | FA MD e−3 |
L R L R |
0.51 (0.05) 0.47 (0.04) 0.80 (0.04) 0.80 (0.03) |
0.51 (0.05) 0.48 (0.04) 0.82 (0.02) 0.81 (0.04) |
0.38 0.24 0.21 0.64 |
0.50 (0.05) 0.50 (0.05) 0.8 (0.04) 0.9 (0.01) |
0.48 (0.05) 0.47 (0.03) 0.8 (0.02) 0.8 (0.03) |
| ATR | FA MD e−3 |
L R L R |
0.45 (0.04) 0.47 (0.03) 0.74 (0.03) 0.76 (0.02) |
0.45 (0.04) 0.45 (0.02) 0.77 (0.02) 0.79 (0.03) |
0.15 0.001* 0.69 0.2 |
0.49 (0.02) 0.47 (0.05) 0.77 (0.02) 0.78 (0.03) |
0.47 (0.01) 0.46 (0.01) 0.77 (0.02) 0.77(0.03) |
| CCG | FA MD e−3 |
L R L R |
0.55 (0.1) 0.52 (0.04) 0.75 (0.04) 0.74 (0.03) |
0.54 (0.1) 0.53 (0.04) 0.79 (0.01) 0.79 (0.05) |
0.0026*
0.5 0.43 0.52 |
0.48 (0.06) 0.53 (0.02) 0.8 (0.01) 0.8 (0.01) |
0.57 (0.01) 0.57 (0.01) 0.77 (0.04) 0.76 (0.05) |
| CAB | FA MD e−3 |
L R L R |
0.38 (0.06) 0.41 (0.05) 0.82 (0.06) 0.82 (0.01) |
0.39 (0.06) 0.40 (0.05) 0.87 (0.06) 0.91 (0.01) |
0.95 0.13 0.51 0.36 |
0.39 (0.07) 0.42 (0.06) 0.88 (0.08) 0.93 (0.01) |
0.38 (0.05) 0.42 (0.05) 0.9 0(0.01) 0.84 (0.07) |
| CST | FA MD e−3 |
L R L R |
0.59 (0.02) 0.57 (0.03) 0.71 (0.02) 0.72 (0.02) |
0.58 (0.02) 0.56 (0.03) 0.75 (0.02) 0.77 (0.02) |
0.36 0.49 0.9 0.78 |
0.60 (0.02) 0.57 (0.02) 0.75 (0.04) 0.82 (0.01) |
0.60 (0.02) 0.58 (0.04) 0.84(0.02) 0.71 (0.07) |
| UF | FA MD e−3 |
L R L R |
0.45 (0.02) 0.44 (0.03) 0.79 (0.02) 0.80 (0.04) |
0.45 (0.03) 0.43 (0.03) 0.82 (0.03) 0.84 (0.03) |
0.84 0.0025* 0.8 0.0022* |
0.46 (0.05) 0.45 (0.04) 0.81 (0.05) 0.83 (0.04) |
0.44 (0.01) 0.45 (0.02) 0.82 (0.04) 0.82 (0.04) |
L, Left; R, Right.
*
P-value corrected for multiple comparison of 18 tracts (P = 0.0028).